Member Content

Recent Biotech IPO Focused on Neurodegenerative Diseases Targeting 2022 Approvals

by Alex Wolsky | Jan 18, 2022

Amylyx Pharmaceuticals (AMLX) an interesting recent IPO in the biotech space worth taking a deeper look into after insiders very active in buying the opening at $19 (four different directors for > $800K) while Viking Global bought a $43.7M positio...

Please login to continue reading this article.

Options Hawk Max

$300 | 30 days

Options Hawk Trading Hub Live Chat
Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
Live Mock Portfolio
1 on 1 Access
Hawk’s Trader Toolbox
Street Research
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
Weekly and Monthly OpEx Sheets
Notable Options Database
OptionsHawk Quarterly Market Brief

More About this Plan

Options Hawk Elite

$149 | 30 days

Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
OptionsHawk Quarterly Market Brief

More About this Plan